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Mantlecelllymphoma(MCL)accountsforlessthan10percentofallnon-Hodgkin’slymphoma(NHL).Pathologicorspontaneous
ruptureofthespleenhasbeenreportedinpatientswithlymphoma;howeveronly5caseshavebeenreportedinpatientswithMCL.
Although splenomegaly occurs frequently in patients with MCL, spontaneous splenic rupture is rare. We present a case of a 51-
year-old female with MCL, who presented to the medical emergency room with splenic rupture. This case illustrates that clinicians
should be aware of the incidence and presentation of patients with MCL and spontaneous splenic rupture, as early detection and
heightened suspicion may prevent potentially fatal outcomes.
1.Introduction
Pathologic or spontaneous rupture of the spleen is a rare
occurrenceandisusuallyassociatedwithinfectionsormalig-
nancy [1]. Although spontaneous splenic ruptures from an
infectious etiology such as malaria, infectious mononucle-
osis, and typhoid have been reported, splenic rupture sec-
ondary to malignancy is infrequent [2]. Spontaneous splenic
rupture in patients with hematologic malignancies was ﬁrst
described by Rokitansky et al. in [3], followed by further
reports of spontaneous splenic rupture in patients with
leukemia over the next century. In 1966, Knoblich et al. [4]
reported three cases of spontaneous splenic rupture in
patients with leukemia [1]; since 1966, approximately 146
more cases of splenic rupture in the setting of malignancy
have been reported. Although the vast majority of these cases
occurred in patients with hematologic malignancies such as
leukemia, approximately 25 percent of these cases occurred
in patients with non-Hodgkin’s lymphoma (NHL). Mantle
cell lymphoma (MCL), which accounts only for 3 to 10
percent of all NHL, has been rarely associated with splenic
rupture, with only ﬁve cases being reported in our literature
review [5–9]. We present a case of a spontaneous splenic
rupture in a 51-year-old female with MCL.
2. Case Presentation
A 51-year-old African American female with a medical
history signiﬁcant for diabetes mellitus and NHL presented
to the medical emergency room with complaints of dizziness
for nearly 12 hours. The patient stated that she noticed the
abruptonsetofdizzinesswhileatrest,whichshedescribedas
persistent and not related to changes in position. She denied
any nausea, vomiting, headaches, fevers, chills, abdominal
pain, and fatigue. She denied the use of any medications at
home as her diabetes mellitus was diet controlled. She was
recently diagnosed with NHL 2 months before, and was
currently being evaluated by her oncologist for varying
therapeutic options. She denied the use of any illicit drugs,
tobacco, and alcohol. Family history was noncontributory,
including the absence of any malignancy.2 Case Reports in Medicine
Table 1: Immunohistochemical staining results.
Antigen Result
CD 20 Positive
CD 10 Negative
CD 5 Positive
BCL-2 Positive
CYCLIN D-1 Positive
CD 23 Negative
CD: cluster of diﬀerentiation; BCL: B-cell lymphoma.
In the emergency room, the patient was lethargic, pale,
and appeared to be in moderate distress. Vital signs recorded
on initial examination revealed the presence of hypotension
and tachycardia, with ﬂuid resuscitation only modestly
increasing the patient’s systolic blood pressure to 80mmHg.
Physical examination was remarkable for moderate abdom-
inal distention with marked hepatosplenomegaly. There was
no abdominal tenderness noted.
Complete blood count (CBC) was signiﬁcant for
hemoglobin of 6.1g/dL, hematocrit of 19 percent, and a
platelet count of 41,000/mm3. An emergent chest radiograph
revealed the presence of an elevated right diaphragm, likely
secondary to marked hepatosplenomegaly. Prior to the ini-
tiation of further diagnostic and therapeutic interventions,
the patient was again noted to be hypotensive with a sys-
tolic blood pressure of 60mmHg. The patient was now
minimally responsive with absent peripheral pulses, thus
cardiopulmonaryresuscitationwasinitiated.Despitenumer-
ous therapeutic interventions such as the administration
of vasopressors, mechanical intubation, and other measures
outlined in Advanced Cardiac Life Saving (ACLS) protocols,
the patient expired.
An autopsy performed revealed a markedly enlarged
spleen measuring 30cm × 20cm × 10cm, weighing 6400
grams, with multiple foci of capsular lacerations noted (Fig-
ure1).Hemoperitoneumoffreshandclottedbloodamount-
ing to approximately 1000mL was also noted. Histopatho-
logic examination of splenic tissue showed massive nodular
inﬁltration of the spleen by small cleaved lymphocytes
(Figures 2 and 3). Immunohistochemistry results supported
the diagnosis of NHL of mantle cell type (Figures 4 and 5;
Table 1).
3. Discussion
MCL accounts for less than 10 percent of all NHL. Typical
morphologic features of MCL are monomorphic lymphoid
proliferation of small- to medium-sized cells with slight to
markedly irregular nuclear contours [5, 10]. The diagnosis
ofMCLisusuallyconﬁrmedbyimmunohistochemicalstain-
ing,withsuggestiveﬁndingsincludingCD5,CD20,andmost
importantly cyclin D1 positivity. Overexpression of cyclin
D1 correlates with the t(11;13) translocation of the short
arm of chromosome 13 which is highly speciﬁc for MCL
a n di su s e dt od i ﬀerentiate with other potential morphologic
mimics such as chronic lymphocytic leukemia/small cell
Figure 1: Gross specimen of a massive spleen weighing 6400 grams
Note the multiple capsular lacerations present (arrows).
Figure 2: Liver tissue with a nodular pattern of lymphocytic
inﬁltration noted.
lymphoma (CLL), follicular lymphoma (FL), and marginal
zone lymphoma (MZL) [6].
Splenic enlargement occurs in nearly 40 percent of
patients with MCL; however splenic rupture is infrequent.
The suggested mechanism of splenic rupture in malignancy
includes splenic enlargement, splenic and capsular inﬁltra-
tion by lymphoma, and eventual splenic infarction leading
to capsular hemorrhage [1, 5, 11, 12]. Although splenic
enlargement itself poses the greatest risk for potential splenic
rupture, other factors have been postulated to account for
suchoccurrences[1,11].Theriskofsplenicruptureincreases
dramatically with age. This observation is most likely related
to the diﬀerence in hematologic cell types and anatomical
abnormalities rendering the spleen more vulnerable [11, 12].
Induction chemotherapy directed towards the preexisting
malignancy may also be a potential risk factor for splenic
rupture. It is believed that the release of enzymatic content
of the cells shortly after induction chemotherapy can lead to
splenic damage that ultimately leads to pathologic rupture
[11]. Fungal infections in patients with malignancy can also
predispose patients to splenic rupture. Fungal granulomas of
the spleen may potentiate rupture by further weakening the
capsule in an already compromised spleen. This is especially
true with Aspergillus spp. which are angioinvasive organisms
causing erosion and occlusion of blood vessels, thereby
increasing the risk for splenic rupture [12]. Variation in
speciﬁc subtypes of MCL, male sex, and aggressiveness ofCase Reports in Medicine 3
Figure 3: Histopathology of splenic tissue. Note the presence of
small cleaved cells (centrocytes) suggestive of mantle cell non-
Hodgkin’s lymphoma.
Cyclin
Figure 4: Immunohistochemical staining positive for cyclin D-
1 correlating with the t(11;13) translocation of the short arm of
chromosome 13, which is highly speciﬁc for MCL.
disease have also been thought to be additional risks for
splenic rupture in patients with MCL [1, 8, 11–13]. Special
attention to these risk factors with prophylactic splenectomy
in patients with multiple risks could prevent these fatal
outcomes.
The presentation of splenic rupture in a patient varies,
often posing a diagnostic challenge for clinicians. The most
common clinical feature of splenic rupture is abdominal
pain, which has been reported to be present in nearly 70
percent of cases. The absence of abdominal pain; however,
should not waver the clinical suspicion of splenic rupture
in patients with malignancy and potential risk factors for
this occurrence. In a study by G¨ org et al. [14], 41 cases of
patients with splenic rupture were reviewed, with only 60
percent of them ever complaining of abdominal pain prior
to diagnosis [14]. Griﬃths et al. report a case of splenic
rupture and subsequent hemoperitoneum in the absence
of abdominal pain, similar to that of our described case
[15]. Nausea, vomiting, fever, and chills have been reported
in cases of splenic rupture, as have signs of hemodynamic
compromise such as hypotension and tachycardia. Kehr’s
sign, which is deﬁned as left hypochondriac pain radiating
to the left shoulder, occurs in nearly 20 percent of patients,
however, is neither sensitive nor speciﬁc for splenic rupture
[11].
BCL-2
Figure 5: Immunohistochemical staining revealing BCL-2 positiv-
ity.
Diagnosis of a spontaneously ruptured spleen relies on
both clinical and conﬁrmatory imaging studies [16]. The
sensitivity of ultrasound for detecting splenic pathology
ranges from 72 to 78% with a speciﬁcity of 91–100% [14].
Combined with the availability, portability, and minimal
patient preparation, ultrasoundisavitaltoolin screening for
a ruptured spleen. Other diagnostic tests include computed
tomography (CT), positron emission tomography (PET),
and diagnostic peritoneal lavage [11, 15]. Prompt diagnosis
and surgical intervention for a ruptured spleen are essential
for patient survival since the mortality rate from splenic
rupture approaches 100% [1, 15, 16]. Given the high
mortality rate of splenic rupture, heightened suspicion for
such an occurrence is warranted.
In our literature review, no single laboratory or imaging
studies will accurately predict impending splenic rupture.
The earliest evidence of splenic injury would include low-
grade lesions such as perisplenic blood without subcapsular
splenic hematoma or intraparenchymal bleed referred to
as a “sentinel clot” [14]. This low-grade splenic injury
has the potential to develop into a subcapsular hematoma
with subsequent splenic rupture [14, 15]. Combined with
lymphoma-induced thrombocytopenia and coagulopathy,
these low-grade lesions are at higher risk for progression
in lymphoma than in other causes of splenomegaly. Athale
et al. suggested that improved imaging techniques and
increased utilization of imaging studies may account for a
rise in incidental detection of “preclinical” splenic rupture.
Surveillance imaging using ultrasound or CT scanning for
the presence of a “sentinel clot” in patients with hematologic
malignancies is therefore recommended [12].
The understanding of potential splenic rupture should
guide clinicians in regards to therapeutic options for patients
with MCL. Treatment of MCL depends on the stage of the
disease and the presence of B symptoms. Early stages I and
II, which accounts for 15 to 25% of low-grade lymphomas,
radiotherapy with or without combination chemotherapy
represents the treatment of choice and may be applied with
curative intent. Asymptomatic advanced MCL, stages III
and IV, may be observed carefully until the disease pro-
gresses and/or symptoms occur since a fraction of patients
present with a rather indolent form of MCL. Immediate4 Case Reports in Medicine
treatment is advocated in advanced symptomatic patients
or highly aggressive lymphoma who can tolerate combined
chemotherapy. Caution during induction chemotherapy is
suggested, as this is known to be a potential risk for
worsening cytopenia, tumor lysis syndrome, and splenic
rupture [12, 17].
In the event of spontaneous splenic rupture, both non-
surgicalandsurgicalmodalitiesexist.Althoughnonoperative
management including packing and arterial embolization
has been attempted, nonoperative management has been
associated with a high mortality and is seldom used today
[1, 8].
Splenectomy in NHL plays an important role in pal-
liation of symptoms of splenomegaly such as left upper
quadrant pain, early satiety, weakness, and fatigue. Other in-
dications for splenectomy include cytopenia, residual
splenomegaly in patients successfully responding to chemo-
therapy in other sites, and a rapidly enlarging spleen at risk
for rupture prior to enrollment in clinical drug trials [18–
21]. Although splenectomy is often performed to alleviate
symptoms of splenomegaly, clinicians should be aware of
potential splenic rupture in patients with NHL, including
MCL. This awareness, along with the identiﬁcation of risk
factors for spontaneous splenic rupture, may prompt pro-
phylactic splenectomy in appropriate patients. Prophylactic
splenectomy may therefore aid in preventing the possibly
fatal consequence of splenic rupture in patients with MCL.
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